OPKO Health, Inc. (NASDAQ:OPK) Given Average Rating of “Hold” by Analysts

Shares of OPKO Health, Inc. (NASDAQ:OPK) have been given an average rating of “Hold” by the seven brokerages that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have issued a hold rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $2.2833.

Several equities research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of OPKO Health from a “sell” rating to a “hold” rating in a research note on Sunday, December 21st. Barrington Research reissued an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Thursday, October 30th. JPMorgan Chase & Co. started coverage on OPKO Health in a research report on Thursday, November 20th. They set a “neutral” rating for the company. Jefferies Financial Group reaffirmed a “hold” rating and issued a $1.60 target price (down from $2.00) on shares of OPKO Health in a research report on Thursday, October 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a research note on Thursday.

Insiders Place Their Bets

In other news, CEO Phillip Md Et Al Frost bought 580,000 shares of OPKO Health stock in a transaction on Friday, November 21st. The stock was purchased at an average cost of $1.33 per share, with a total value of $771,400.00. Following the purchase, the chief executive officer directly owned 216,706,448 shares of the company’s stock, valued at approximately $288,219,575.84. This trade represents a 0.27% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders have bought 1,843,300 shares of company stock valued at $2,421,491. Company insiders own 49.69% of the company’s stock.

Hedge Funds Weigh In On OPKO Health

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Caprock Group LLC bought a new position in OPKO Health in the 3rd quarter worth approximately $26,000. Swiss Life Asset Management Ltd bought a new stake in OPKO Health during the 3rd quarter valued at $30,000. Savant Capital LLC bought a new stake in OPKO Health during the 3rd quarter valued at $33,000. Arrow Financial Corp acquired a new position in OPKO Health during the 3rd quarter worth $39,000. Finally, Fisher Asset Management LLC bought a new position in shares of OPKO Health in the second quarter worth $40,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

OPKO Health Stock Performance

Shares of OPK opened at $1.32 on Monday. The stock has a market capitalization of $1.01 billion, a PE ratio of -5.28 and a beta of 1.39. The business’s fifty day moving average price is $1.32 and its 200 day moving average price is $1.37. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.70 and a quick ratio of 3.32. OPKO Health has a 12-month low of $1.11 and a 12-month high of $2.04.

OPKO Health (NASDAQ:OPK) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.05. OPKO Health had a negative net margin of 28.10% and a negative return on equity of 13.67%. The company had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $165.74 million. During the same period in the prior year, the company earned $0.03 earnings per share. The firm’s revenue was down 12.6% compared to the same quarter last year. Equities research analysts forecast that OPKO Health will post -0.25 EPS for the current year.

About OPKO Health

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.